Mercer Global Advisors’s Cardiff Oncology CRDF Stock Holding History

Mercer Global Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-147,857	Closed	-$207K	–	1953
2022 Q4	$207K	Hold	147,857	–	–	﹤0.01%	1698
2022 Q3	$228K	Hold	147,857	–	–	﹤0.01%	1566
2022 Q2	$325K	Hold	147,857	–	–	﹤0.01%	1386
2022 Q1	$367K	Sell	147,857 -40,500	-22%	-$143K	﹤0.01%	1401
2021 Q4	$1.13M	Buy	188,357 +15,000	+9%	+$89.4K	0.01%	830
2021 Q3	$1.16M	Buy	173,357 +5,500	+3%	+$34.5K	0.01%	793
2021 Q2	$1.12M	Buy	167,857 +10,000	+6%	+$84.8K	0.01%	785
2021 Q1	$1.46M	Buy	157,857 +22,007	+16%	+$267K	0.01%	642
2020 Q4	$2.44M	Hold	135,850	–	–	0.03%	374
2020 Q3	$1.93M	Buy	135,850 +200	+0.1%	+$1.32K	0.03%	392
2020 Q2	$680K	Buy	+135,650	New	+$278K	0.01%	580

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Mercer Global Advisors's CRDF Position: Q1 2023 in Review

Mercer Global Advisors sold out of Cardiff Oncology (CRDF) in Q1 2023, closing a stake of 147,857 shares — an estimated $207K sold.

Mercer Global Advisors first reported a position in CRDF in Q2 2020 and held it in 11 quarters. The position peaked at $2.44M in Q4 2020. 55 funds tracked by Wall St. Rank hold CRDF as of Q1 2023.

Mercer Global Advisors reported no remaining Cardiff Oncology position as of Q1 2023 after selling out during the quarter.
Mercer Global Advisors sold 147,857 Cardiff Oncology shares in Q1 2023, an estimated $207K.
Mercer Global Advisors first reported a position in Cardiff Oncology in Q2 2020 and held it in 11 quarters.
Mercer Global Advisors's Cardiff Oncology position peaked at $2.44M in Q4 2020.
55 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2023.

Based on Mercer Global Advisors's 13F filing for Q1 2023, filed 16 May 2023.